The company’s conclusion rests on a comprehensive safety dossier developed through rigorous preclinical and clinical testing. An independent panel of expert toxicologists reviewed the data, which includes studies on genotoxicity, human tolerability, and pharmacokinetics. By publishing these findings in journals such as Nutrients and the Journal of the International Society of Sports Nutrition, cbdMD aims to transition hemp-derived wellness into a more evidence-based regulatory environment.
cbdMD Sets 200mg Daily Safety Benchmark for Broad Spectrum CBD
A self-affirmed Generally Recognized as Safe (GRAS) determination now supports the consumption of up to 200 mg of cannabidiol per day in healthy adults. This milestone, announced by Charlotte-based cbdMD, follows years of peer-reviewed toxicological and clinical studies designed to establish a definitive ceiling for daily hemp-derived product intake.
This development arrives as federal policy shifts toward integrating CBD into mainstream healthcare. With the Centers for Medicare & Medicaid Services launching initiatives that allow physician-guided access to third-party-tested hemp products, the industry faces increased pressure to provide verifiable safety standards. According to CEO Ronan Kennedy, the investment in this scientific portfolio is intended to offer clinicians and retail partners a reliable reference point for consistent, responsible product usage across the firm’s entire catalog.
Comments (0)
No comments yet. Be the first!